Is long sleep duration a new risk factor for obesity?

Sleep is an important modulator for neuroendocrine functions and glucose metabolism. However the data about the relation between long sleep duration and obesity is scarce and unclear, so herein we evaluated both long and short sleep durations either with high or poor quality: within different age and obesity groups to define the interaction between obesity and sleep. Here in our group most of the patients (79.6%) sleeping longer than 8 hours-long sleepers- were either obese (49%) or morbid obese (30.6%) and long sleep duration was significantly common compared to control group (79.5% vs. 6%; and P < 0.001). We can conclude that as well as short sleep duration; long sleep duration has to be taken into concern as a cause or result of obesity

Seroepidemiology of Hepatitis B Virus Infection in Istanbul: A 20-year Survey

Objective: Turkey is an intermediate endemic country for hepatitis B virus (HBV) infection, with the prevalence rates showing regional differences. The aim of this study was to determine the recent prevalence of HBV infection among adults in Istanbul and to evaluate the impact of national vaccination program that started in 1998

Changes in the prevalence of HBV infection in pregnant women in Turkey between 1995 and 2015: a 20-year evaluation

Objective To determine changes in hepatitis B virus (HBV) prevalence across three different time periods in pregnant women

Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy

Abstract Background The importance of COVID-19 vaccination for patients on immunosuppressive (IS) medication has increased due to the high risk of severe disease or mortality. Different vaccines have varying efficacy rates against symptomatic COVID-19, ranging from 46.8% to 95%. The objective of this study was to examine the differences in anti-Spike IgG, anti-Spike IgA, and neutralizing antibody (NAb) activity between the inactive CoronaVac vaccine and the mRNA-based BNT162b2 vaccine in IS patients. Method A total of 441 volunteers, including 104 IS patients, 263 healthy controls (HC), who received two doses of CoronaVac or BNT162b2, and 74 unvaccinated patients with a history of SARS-CoV-2 infection, were included in the study. Anti-spike IgG, IgA, and NAb activity were investigated. Results Immunogenicity with BNT162b2 was higher than with CoronaVac, but in IS groups, it was lower than HC (CoronaVac-IS: 79.3%, CoronaVac-HC: 96.5%, p < 0.001; BNT162b2-IS: 91.3%, BNT162b2-HC: 100%, p = 0.005). With CoronaVac, anti-Spike IgG levels were significantly lower than BNT162b2 (CoronaVac-IS: 234.5AU/mL, CoronaVac-HC: 457.85AU/mL; BNT162b2-IS: 5311.2AU/mL, BNT162b2-HC: 8842.8AU/mL). NAb activity in the BNT162b2 group was significantly higher. NAb and anti-Spike IgG levels were found to be correlated. Among the IS group, a significantly lower response to the vaccines was observed when using rituximab. IgA levels were found to be lower with CoronaVac. Conclusions Although immunogenicity was lower in IS patients, an acceptable response was obtained with both vaccines, and significantly higher anti-Spike IgG, anti-Spike IgA, and NAb activity levels were obtained with BNT162b2